29 maj: Europæiske aktier: Nye stryg til Spanien i positivt marked
30 maj: Selskabernes forventninger - onsdag den 30 maj
29-05-2012 22:39:00

UPDATE: J&J Unit Gets FDA Warning Letter On K-Y Vaginal Moisturizer

Relateret indhold
Relateret debat
05 aug - 
Lige for en sikkerhedsskyld kan du jo tænke lidt mens d..
05 aug - 
Lige præcis, dvs. Novo har bedre forudsætninger end J&J..
05 aug - 
Fortiden er ligegyldig, fremtien er hvad betyder noget ..

(Updates with McNeil statement starting in the third paragraph.)

--FDA warns J&J unit on failure to properly investigate some consumer complaints

--Most of the letter details problems related to K-Y vaginal moisturizer

--FDA says a reporting problem related to O.B. Tampons has been adequately addressed

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration said a Johnson & Johnson (JNJ) unit didn't properly investigate consumer complaints related to a vaginal moisturizer.

The agency, in a warning letter dated May 22, said the company received more than 200 complaints about K-Y liquibeads vaginal moisturizer, which is made by McNeil PPC Inc., from June 25, 2010, through Dec. 12, 2011. The agency said the complaints included reports of the product not dissolving or having an uncharacteristic consistency or texture. FDA said some of the complaints were closed without being investigated by the company. McNeil also didn't adequately investigate some complaints that contained an incorrect lot number, according to FDA.

In a statement, McNeil said it takes the issues raised by FDA seriously. "We will respond fully to their concerns and take whatever steps are needed to resolve these issues," the company said.

The warning letter was posted to the FDA's website on Tuesday. The letter stems from an inspection conducted by the FDA of a McNeil facility in Skillman, N.J. on Dec. 12, 2011 through Jan. 19, 2012.

The FDA also said the company was late in submitting a report about a person being diagnosed with toxic shock syndrome after using an O.B. Tampon, also made by McNeil. However, the FDA said the company had adequately responded to the agency's concerns about that report.

Johnson & Johnson's McNeil Consumer Healthcare unit has been working to address manufacturing problems that led to recalls of Tylenol and other over-the-counter products starting in 2009. Three of the company's manufacturing plants were placed under an FDA consent decree last year and one of the plants, in Fort Washington, Pa., is still shut down.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

(END) Dow Jones Newswires

May 29, 2012 16:39 ET (20:39 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Glunz FY: Ingen udbytte i vente efter ventet underskud

25-08-2016 15:09:39
Der var underskud på bundlinjen for Glunz & Jensen, der blandt andet laver og sælger udstyr til trykkerier, i det netop overståede regnskabsår, der løb fra 1. j..

Alm. Brand/CEO: Tre årsager til samlet opjustering

25-08-2016 13:00:16
Alm. Brand-koncernen kunne i torsdag morgens regnskab for andet kvartal opjustere forventningerne til hele årets resultat før skat med 100 mio. kr.Langt største..

ATP/CEO: Dong Energy skæppede med 2,9 mia. kr. - NY

25-08-2016 11:06:43
Pensionsgiganten ATP fik i første halvår et investeringsafkast på 6,7 pct. svarende til 6,9 mia. kr. Mens man tabte på udenlandske aktier - de japanske især - s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Zealand H1: Venter bedste år nogensinde med bredere portefølje
2
Aktier/tendens: Strøm af regnskaber ventes at dominere
3
Parken/Nordnet: Aktien kan stige tocifret efter opjustering
4
Torsdagens aktier: Pandora på pinebænken efter USA-skuffelse
5
Aktier/middag: Regnskabsvrimmel med plus til Sydbank

Relaterede aktiekurser

Johnson & Johnson 118,57 -0,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. august 2016 20:25:24
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160823.1 - EUROWEB3 - 2016-08-25 20:25:24 - 2016-08-25 20:25:24 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x